HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026
— Registration-enabling study demonstrated high clinically meaningful objective responses, achieving rapid and durable disease control —
— Registration-enabling study demonstrated high clinically meaningful objective responses, achieving rapid and durable disease control —
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.